New Gene Therapy Study in Friedreich’s Ataxia (FA) Sponsored by LEXEO Therapeutics, Inc

The study is being conducted with multiple sites in the United States and Canada seeking to recruit approximately 9 participants aged 18-40 with a diagnosis of FA-associated cardiomyopathy. The study will be conducted by Dr. Antoine Duquette at the CHUM in Montreal. The choice of Montreal as a site reflects...

Continue reading

U.S. Food & Drug Administration Approves Reata Pharmaceuticals’ SKYCLARYS™ for the Treatment of Adults and Adolescents Aged 16 Years and Older with Freidreich Ataxia

U.S. Food & Drug Administration Approves Reata Pharmaceuticals’ SKYCLARYS™ (Omaveloxolone) for the Treatment of Adults and Adolescents Aged 16 Years and Older with FA   Montreal,QC ., February 28, 2023 – This week  marks the approval of the first medication to treat Friedreich’s Ataxia (FA), a milestone for the FA...

Continue reading

Clinical Research Consortium for the Study of Cerebellar Ataxia (CRC-SCA)

The National Ataxia Foundation today announced that the Centre hospitalier de l’Université de Montréal (CHUM) will be the first international clinical site to join the Clinical Research Consortium for the Study of Cerebellar Ataxia (CRC-SCA). The CRC-SCA is a group of clinical research sites across the United States actively enrolling...

Continue reading